Irritable Bowel Syndrome Epidemiology

• Irritable Bowel Syndrome (IBS) is a common chronic disorder of gut–brain interaction characterized by recurrent abdominal pain associated with altered bowel habits, including diarrhea, constipation, or a mixed stool pattern, significantly affecting quality of life and daily functioning. 
• IBS is one of the most prevalent functional gastrointestinal disorders worldwide. As per secondary analysis, the total prevalence of irritable bowel syndrome in the US is 14.1% (medically diagnosed: 3.3%; undiagnosed but meeting criteria: 10.8%). 
• IBS can affect individuals of all ages and both sexes; however, it is more frequently reported in women and is most commonly diagnosed in early and middle adulthood. 
• The pathophysiology of IBS is multifactorial and involves disturbances in the gut–brain axis, altered gastrointestinal motility, visceral hypersensitivity, immune activation, intestinal barrier dysfunction, gut microbiota alterations, and psychosocial factors. 
• The burden of IBS is increasing due to growing awareness of the disease, evolving diagnostic approaches, lifestyle and dietary changes, and the substantial impact of chronic gastrointestinal symptoms on healthcare utilization and work productivity. 
• Additional risk factors associated with IBS include female sex, younger age, a history of gastrointestinal infections, psychological stress, anxiety, depression, sleep disturbances, and a family history of gastrointestinal disorders. 
• IBS is a heterogeneous disorder with distinct subtypes, including IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and mixed IBS (IBS-M), contributing to variability in symptom presentation and disease burden across patient populations. 
• Increasing recognition of the complex interplay between gastrointestinal, neurological, immune, and microbiome-related factors has expanded understanding of IBS epidemiology and disease mechanisms, driving continued research interest during the forecast period. 

Irritable Bowel Syndrome (IBS) Epidemiology Forecast

DelveInsight’s “Irritable Bowel Syndrome (IBS) – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of IBS  historical and forecasted epidemiology trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The Irritable Bowel Syndrome (IBS) epidemiology report provides a comprehensive analysis of prevalent cases, capturing the number of patients across the 7MM. It includes detailed segmentation by gender, age, severity and subtype along with regional distribution. The report evaluates historical and forecasted prevalence trends (2026–2036), highlighting variations in disease occurrence and diagnosis patterns, and offering insights into the evolving burden of newly diagnosed IBS cases.

Geography Covered 

North America: The United States 

Europe: Germany, France, Italy, and Spain and the United Kingdom

Asia-Pacific: Japan

Irritable Bowel Syndrome (IBS) Understanding

Irritable Bowel Syndrome (IBS) Overview and Diagnosis

IBS is a common functional gastrointestinal disorder characterized by recurrent abdominal pain associated with altered bowel habits, including diarrhea, constipation, or a combination of both, in the absence of identifiable structural or biochemical abnormalities. IBS is a heterogeneous condition that is broadly classified into IBS-C, IBS-D, IBS-M, and unsubtyped IBS (IBS-U). Although the exact etiology remains incompletely understood, the disorder is believed to result from a complex interplay among altered gastrointestinal motility, visceral hypersensitivity, dysregulation of the gut-brain axis, intestinal immune activation, changes in gut microbiota composition, and psychosocial factors. Patients commonly experience symptoms such as abdominal pain, bloating, abdominal distension, and altered stool frequency or consistency, which can substantially impair quality of life and daily functioning.

The diagnosis of IBS is primarily based on clinical evaluation and symptom-based diagnostic criteria, most notably the Rome IV criteria, which define IBS as recurrent abdominal pain associated with defecation and changes in stool frequency or form. Diagnostic assessment typically includes a detailed medical history, physical examination, and selective laboratory investigations to exclude organic gastrointestinal disorders with overlapping symptoms, such as inflammatory bowel disease, celiac disease, gastrointestinal infections, or colorectal malignancies. Additional diagnostic testing may be performed in patients presenting with alarm features or atypical clinical characteristics. Given the heterogeneous presentation of IBS and its multifactorial pathophysiology, accurate diagnosis and patient stratification are essential for understanding disease burden and characterizing affected patient populations.

Further details related to country-based variations are provided in the report…

Irritable Bowel Syndrome (IBS) Epidemiology

Key Findings from IBS Epidemiological Analysis and Forecast 

• Among the EU4 countries, Germany reported an IBS prevalence of 3.5% based on data from the SHIP-Trend-0 population-based survey by Schauer et al. (2019), whereas Spain demonstrated a wider prevalence range of 3.3% to 14.1%, reflecting differences in the diagnostic criteria used across studies.
• Based on secondary research, the pooled Prevalence of IBS among Italian adults is 7.7%, with estimates ranging from 5.4% to higher values.
• In Japan, Takeoka et al. (2023) reported an IBS prevalence of 14.9% based on the Rome III diagnostic criteria, highlighting a substantial disease burden among adults.
• Major factors contributing to regional differences in the Prevalence and burden of IBS across the 7MM include variations in dietary habits, lifestyle factors, psychosocial stress, healthcare-seeking behavior, diagnostic criteria, healthcare access, and the Prevalence of associated gastrointestinal and psychological comorbidities. The epidemiology of IBS is expected to evolve during the forecast period (2026–2036), driven by increasing disease awareness, broader adoption of standardized diagnostic criteria, growing recognition of gut-brain axis disorders, and improved identification of patients with functional gastrointestinal disorders.

Further details are provided in the report.

Total Prevalent Cases of Irritable Bowel Syndrome (IBS) in the 7MM in 2025

Industry Experts and Physician Views for Irritable Bowel Syndrome (IBS) 

To keep up with IBS epidemiology trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the IBS epidemiology, prevalence trends, regional distribution, patient demographics, diagnostic rates, and real-world disease burden patterns in IBS, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 10+ KOLs to gather insights at country level. Centers such as the Memorial Sloan Kettering Cancer Center, University of California San Francisco, State University of New York Upstate Medical University, etc. were contacted. 

Their opinion helps understand and validate IBS epidemiological trends, highlight key gaps in diagnosis and disease burden, provide deeper epidemiological context, and support strategic decisions for patient identification and disease monitoring in IBS.

Scope of the Report

• The report covers a segment of key epidemiological highlights, an executive summary, and a descriptive overview of IBS, including its causes, risk factors, and factors influencing disease occurrence.
• Comprehensive insights are provided into prevalence trends and forecasts, along with the future growth potential of prevalence rates and evolving patterns of disease detection across the 7MM.
• Additionally, the report includes detailed segmentation of prevalent cases by gender, age, severity and subtype offering a granular view of the epidemiological landscape.
• A thorough assessment of historical and forecasted prevalence data, along with underlying assumptions and methodology, is included, providing a clear understanding of disease burden across the 7MM.
• The report provides strategic insights by highlighting trends in prevalence, diagnostic gaps, and regional variations, supported by expert opinions and epidemiological analysis to better understand and project the IBS disease burden. 

Report Insights

• IBS prevalence forecast, epidemiological burden, segmentation, trends, and opportunity assessment.

Report Key Strengths

• Epidemiology‑based (EPI ‑ based) bottom‑up forecasting
• Artificial Intelligence (AI) - enabled epidemiology research report 
• 11-year forecast 
• IBS epidemiological outlook (North America, Europe, Asia-Pacific) 
• IBS Burden trends (by geography)

Report Assessment

• Irritable Bowel Syndrome (IBS) Diagnostic Trends
• Irritable Bowel Syndrome (IBS) Epidemiological Gaps
• Irritable Bowel Syndrome (IBS) Development Trends
• Irritable Bowel Syndrome (IBS) Emerging Research Focus
• Irritable Bowel Syndrome (IBS) Disease Burden Attractiveness
• Irritable Bowel Syndrome (IBS) Qualitative Epidemiological Insights

FAQs

• What was the IBS prevalent patient population and distribution (%) in 2025, and how will it evolve by 2036? What factors are driving these trends?
• What are the anticipated variations in prevalence and diagnosis rates across different geographies?
• What will be the future diagnosis and epidemiological trends of IBS?
• What are the disease risks, burden, and key epidemiological gaps in IBS? What are the growth opportunities based on the patient population across the 7MM?
• How will changes in prevalence and diagnosis impact the overall epidemiological landscape?
• What are the current diagnosis practices and epidemiology trends of IBS in the US, Europe, UK, and Japan?

Reasons to Buy

• The report will help in developing strategies by understanding the latest trends and changing epidemiology of IBS.
• Bottom-up forecasting builds from the prevalent patient population, delivering a robust, data-driven epidemiological approach.
• Insights on patient burden/prevalence, evolution in diagnosis, and factors contributing to changes in disease epidemiology during the forecast years.
• Understand the epidemiological opportunities across varying geographies and growth potential over the coming years.
• Identifying key trends in disease prevalence will help anticipate shifts in the epidemiological landscape.
• Detailed analysis and segmentation of prevalent cases to provide visibility around high-burden patient groups.
• To understand KOLs’ perspectives on diagnosis challenges and gaps in disease identification.
• Detailed insights on epidemiological unmet needs to support improved disease tracking and diagnosis strategies.
• This Artificial Intelligence (AI)-enabled report summarizes complex epidemiological datasets into clear, actionable insights for stakeholders, investors, and healthcare providers.